Clinical trial NCT04817891: Stimulation of Cingulo-opercular Alertness Network
Official title: Cholinergic Functions and Modulation of the Cingulo-opercular Alertness Network in LBD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lewy Body Disease
Lewy Body Variant of Alzheimer Disease
Lewy Body Dementia With Behavioral Disturbance
Keywords: Lewy Body Dementia
Cognitive
Thinking
Cognition
Cognitive Rehabilitation
Brain Stimulation
Imaging
Lewy Body
Dementia
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: National Institute on Aging (NIA)
First posted: 2021-03-26
Enrollment: 15
Sex: ALL
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Eligible participants receive individualized intervention/stimulation based on their fMRI and PET imaging.
Primary purpose: TREATMENT

Brief summary: Fluctuations in alertness are very common in persons with Lewy body dementias and are a major source of disability. Changes in a chemical messenger molecule called acetylcholine within certain brain regions may play a role in these fluctuations. We propose to test this hypothesis and also determine whether a non-invasive way of stimulating affected brain regions may be of relevance for future management of these fluctuations.

Detailed description: The central premise of the research study is that cholinergic system changes in specific neural network regions underlie cognitive fluctuations in patients with LBD. The cingulo-opercular task control (COTC) neural network is believed to play a role in maintenance of alertness but this remains uncertain in LDB. This critical knowledge gap forms the basis of our first aim. The study proposes to use transcranial direct current stimulation (tDCS) to "excite" critical cholinergic denervation components of the COTC as an adjunct to cholinergic pharmacotherapy in a target engagement study. tDCS is an emerging non-invasive neurostimulation technology that may improve a range of neurological symptoms, including cognition. The study will evaluate whether target engagement by tDCS excitation of cholinergic denervated COTC hubs may affect cognitive fluctuations in LBD subjects.

Eligibility criteria: Inclusion Criteria:

* LBD patients (DLB or PDD) who have cognitive fluctuations and who are on stable doses of cholinesterase inhibitors (i.e., at least 4 weeks) will be recruited to participate in this study.
* DLB patients will meet the Fourth consensus report of the DLB Consortium inclusion criteria for probable DLB.
* Subjects will be identified according to the following recognized DLB features: spontaneous parkinsonian motor signs, fluctuating attention and concentration, recurrent well-formed visual hallucinations, presence of REM behavioral sleep disturbance, anosmia/hyposmia,or autonomic dysfunction.
* PDD patients will meet the criteria by Emre et al. (Cognitive deficits in at least two of four of the following cognitive domains: Impaired attention, impaired executive functions, impairment in visuo-spatial functions, impaired free recall memory typically improved with cuing. Must also meet criteria for at least one behavioral symptom: apathy, depressed or anxious mood, hallucinations, delusions, excessive daytime sleepiness). Lack of behavioral symptoms does not exclude the diagnosis. Must also have none of Group III features present: (1) Co-existance of any other abnormality which might cause impairment, but judged not to be the cause of dementia. (2) Time interval between development of motor and cognitive symptoms not known. Must also have none of Group IV symptoms present: (1) Cognitive and behavioral symptoms appear solely in the context of other conditions such as acute confusion caused by systemic diseases or abnormalities, drug intoxication, or major depression according to DSM IV. (2) Features compatible with Probable Vascular Dementia criteria accordingly to NINDS-AIREN.

Exclusion Criteria:

* Subjects with contra-indications to MR imaging and/or tDCS, including pacemakers or claustrophobia
* Evidence of large vessel stroke or mass lesion on MRI
* Use of anti-cholinergic or neuroleptic drugs
* Evidence of atypical parkinsonism on neurological exam
* Major psychiatric illness, such as bipolar disorder
* Neurological conditions such as epilepsy, stroke, multiple sclerosis, or moderate to severe brain injury
* Sensory impairments that significantly limit one's ability to see or hear
* A significant history of recent alcohol or drug dependence
* Previous major radiation exposure
* Pregnancy

Primary outcomes:
measure: Change from Baseline on Dementia Cognitive Fluctuations Scale
timeFrame: Baseline and Post-Testing (3-4 weeks)
Secondary outcomes:
measure: Change from Baseline Resting State fMRI
timeFrame: Baseline and Post-Testing (3-4 weeks)
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: 4251 Plymouth Road (University of Michigan)
state: Michigan
Study officials:
affiliation: University of Michigan
name: Benjamin Hampstead, PhD
role: PRINCIPAL_INVESTIGATOR
References: